CHICAGO — A Fas inhibitor showed strong efficacy signals and demonstrated in patients with more than 8 days of macula-off rhegmatogenous retinal detachment, according to a study. A Fas inhibitor ...
ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback